Stereotactic body radiotherapy for peripheral nonsmall cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2013.12.012

Abstract

Abstract: Stereotactic body radiotherapy (SBRT) can treat the lesions in a "surgical" manner and inhibit tumor cell proliferation. Furthermore, it has a character of "noninvasive", which shortens the duration of treatment. Although surgery and radiotherapy are the major means for early stage peripheral nonsmall cell lung cancer, some studies in recent years show that SBRT has certain advantages in local control ratio and adverse reaction compared with radiotherapy, and acquires the similar curative effect with surgery.

Key words: Carcinoma, nonsmallcell lung, Radiosurgery, Treatment outcome

WANG Wei-Lin, DU Ze-Dong, LI Chang-Lin. Stereotactic body radiotherapy for peripheral nonsmall cell lung cancer[J]. Journal of International Oncology, 2013, 40(12): 918-920.

References

［1］ van Baardwijk A, Tomé WA, van Elmpt W, et al. Is highdose stereotactic body radiotherapy (SBRT) for stage Ⅰ nonsmall cell lung cancer (NSCLC) overkill? A systematic review. Radiother Oncol, 2012, 105(2): 145149. ［2］ Louie A, Rodrigues G, Hannouf M, et al. Stereotactic body radiotherapy versus surgery for medically operable Stage Ⅰ nonsmallcell lung cancer: a Markov modelbased decision analysis. Int J Radiat Oncol Biol Phys, 2011, 81(4): 964973. ［3］ Xiao Y, Papiez L, Paulus R, et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage ⅠⅡ nonsmallcell lung cancer. Int J Radiat Oncol Biol Phys, 2009, 73(4): 12351242. ［4］ VanderWalde A, Pal S, Reckamp K， et al. Management of nonsmallcell lung cancer in the older adult. Maturitas, 2011, 68(4): 311321. ［5］ Bral S, Gevaert T, Linthout N, et al. Prospective, riskadapted strategy of stereotactic body radiotherapy for earlystage nonsmallcell lung cancer: results of a Phase Ⅱ trial. Int J Radiat Oncol Biol Phys, 2011, 80(5): 13431349. ［6］ Chen Y, Guo W, Lu Y, et al. Doseindividualized stereotactic body radiotherapy for T13N0 nonsmall cell lung cancer: longterm results and efficacy of adjuvant chemotherapy. Radiother Oncol, 2008, 88(3): 351358. ［7］ Feddock J, Arnold S, Shelton B, et al. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced nonsmall cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys, 2013, 85(5): 13251331. ［8］ Palma D, Lagerwaard F, Rodrigues G, et al. Curative treatment of Stage Ⅰnonsmallcell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys, 2012, 82(3): 11491156. ［9］ Louie A, Rodrigues G, Hannouf M, et al. Withholding stereotactic radiotherapy in elderly patients with stage Ⅰ nonsmall cell lung cancer and coexisting COPD is not justified: outcomes of a Markov model analysis. Radiother Oncol, 2011, 99(2): 161165. ［10］ Palma D, Visser O, Lagerwaard F， et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage Ⅰ nonsmallcell lung cancer: a populationbased timetrend analysis. J Clin Oncol, 2010, 28(35): 51535159. ［11］ Iwata H, Demizu Y, Fujii O, et al. Longterm outcome of proton therapy and carbonion therapy for large (T2aT2bN0M0) nonsmallcell lung cancer. J Thorac Oncol, 2013, 8(6): 726735. ［12］ Bishawi M, Kim B, Moore W, et al. Pulmonary function testing after stereotactic body radiotherapy to the lung. Int J Radiat Oncol Biol Phys, 2012, 82(1): e107110. ［13］ Takeda A, Enomoto T, Sanuki N, et al. Reassessment of declines in pulmonary function ≥1 year after stereotactic body radiotherapy. Chest, 2013, 143(1): 130137. ［14］ Ohri N, WernerWasik M, Grills IS, et al. Modeling local control after hypofractionated stereotactic body radiation therapy for stage Ⅰ nonsmall cell lung cancer: a report from the elekta collaborative lung research group. Int J Radiat Oncol Biol Phys, 2012, 84(3): e379384. ［15］ Daly M, Perks J, Chen A. Patternsofcare for thoracic stereotactic body radiotherapy among practicing radiation oncologists in the United States. J Thorac Oncol, 2013, 8(2): 202207. ［16］ Olsen JR, Robinson CG, El Naqa I, et al. Doseresponse for stereotactic body radiotherapy in earlystage nonsmallcell lung cancer. Int J Radiat Oncol Biol Phys, 2011, 81(4): e299303. ［17］ Guckenberger M, Allguer M, Appold S， et al. Safety and efficacy of etereotactic body radiotherapy for stage Ⅰ nonsmallcell lung cancer in routine clinical practice: a patternsofcare and outcome analysis. J Thorac Oncol, 2013, 8(8): 10501058. ［18］ Ge H, Cai J, Kelsey C, et al. Quantification and minimization of uncertainties of internal target volume for stereotactic body radiation therapy of lung cancer. Int J Radiat Oncol Biol Phys, 2013, 85(2): 438443. ［19］ Mancosu P, Sghedoni R, Bettinardi V, et al. Semiautomatic technique for defining the internal gross tumor volume of lung tumors close to liver/spleen cupola by 4DCT. Med Phys, 2010, 37(9): 45724576. ［20］ Chi A, Liao Z, Nguyen N, et al. Systemic review of the patterns of failure following stereotactic body radiation therapy in earlystage nonsmallcell lung cancer: clinical implications. Radiother Oncol, 2010, 94(1): 111. ［21］ Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA, 2010, 303(11): 10701076. ［22］ Senthi S, Lagerwaard F, Haasbeek C, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage nonsmallcell lung cancer: a retrospective analysis. Lancet Oncol, 2012, 13(8): 802809.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Wang Kun, Zhou Zhongxin, Zang Qiwei. Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection [J]. Journal of International Oncology, 2024, 51(4): 198-203.
[3]	Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin. Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 137-142.
[4]	Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie. Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(2): 89-94.
[5]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[6]	Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun. Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases [J]. Journal of International Oncology, 2023, 50(3): 138-143.
[7]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[8]	Cao Mengqing, Xu Zhiyong, Shi Yuting, Wang Kai. Role of tertiary lymphoid structures in tumor immune microenvironment regulation and anti-tumor therapy [J]. Journal of International Oncology, 2023, 50(3): 169-173.
[9]	Wang Bing, Wang Aifu, Liu Wenshu, Fan Jiaojiao, Tian Weicheng, Wang Weili, Liu Boyu. The efficacy and safety of recombinant human thrombopoietin in the treatment of thrombocytopenia caused by tumor radiotherapy [J]. Journal of International Oncology, 2023, 50(11): 661-667.
[10]	Liu Song, Yu Guangji, Wang Qingdong. Efficacy and influencing factors of DEBIRI-TACE combined with regorafenib in the third-line or above treatment of colorectal cancer liver metastases [J]. Journal of International Oncology, 2022, 49(7): 400-407.
[11]	Cai Gangxiang, Li Jing, Xu Bin. Advances in neoadjuvant immunotherapy for lung cancer [J]. Journal of International Oncology, 2022, 49(6): 366-370.
[12]	Ding Xinjing, Ding Jianghua. Research progress on the correlation between dermatological immune-related adverse events and clinical outcome of PD-1/PD-L1 inhibitors [J]. Journal of International Oncology, 2022, 49(4): 225-228.
[13]	Lin Rongsheng, Wu Chuhai, Guo Yingmei, Wang Tao, Chen Rongbin, Liu Shaoqin, Gan Bing. Efficacy and safety of teriprizumab combined with bevacizumab in the treatment of metastatic MSI-H colorectal cancer above the second line [J]. Journal of International Oncology, 2022, 49(2): 100-105.
[14]	Wang Bin, Zhou Jiangyun, Liu Xi. Analysis of the clinical value of different radiotherapy schemes in patients with advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2021, 48(8): 484-488.
[15]	Du Xiao, Zhou Juying. Stereotactic body radiotherapy for localized prostate cancer [J]. Journal of International Oncology, 2021, 48(5): 313-316.